Liabilities and Equity in USD of Ambrx Biopharma Cayman, Inc. from Q4 2020 to Q2 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary: Ambrx Biopharma Cayman, Inc. quarterly Liabilities and Equity history and change rate from Q4 2020 to Q2 2023.
Ambrx Biopharma Cayman, Inc. Liabilities and Equity for the quarter ending 30 Jun 2023 was $279,944,000, a 54.8% increase year-over-year.
Source SEC data: View on sec.gov

Liabilities and Equity, Quarterly (USD)

Liabilities and Equity, YoY Quarterly Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Liabilities and Equity (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2023	$279,944,000	+$99,074,000	+54.8%	30 Jun 2023	10-Q	09 Aug 2023	2023	Q2
Q1 2023	$210,613,000			31 Mar 2023	10-Q	11 May 2023	2023	Q1
Q4 2022	$146,977,000	-$82,042,000	-35.8%	31 Dec 2022	10-Q	09 Aug 2023	2023	Q2
Q2 2022	$180,870,000			30 Jun 2022	6-K	29 Aug 2022	2022	Q2
Q4 2021	$229,019,000	+$94,998,000	+70.9%	31 Dec 2021	10-K	30 Mar 2023	2022	FY
Q4 2020	$134,021,000			31 Dec 2020	20-F	26 Apr 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.